This invention provides C-22 substituted rapamycin derivatives of the following formulas: or and pharmaceutically acceptable salts thereof which are useful for inducing immunosuppression and treating transplantation rejection, host vs. graft disease, autoimmune diseases, diseases of inflammation, solid tumors, fungal infections, adult T-cell leukemia/lymphomas and hyperprol...

PCT No. PCT/GB94/01646 Sec. 371 Date Feb. 8, 1996 Sec. 102(e) Date Feb. 8, 1996 PCT Filed Jun. 29, 1994 PCT Pub. No. WO95/05194 PCT Pub. Date Feb. 23, 1995The invention provides the use of Hepatitis A virus capsid, or a mucosally immunogenic fragment or epitope thereof, for the manufacture of a mucosal vaccine composition for administration to a mucosal surface of a patient to induce production of...

Compounds of formula (I) wherein R<1> and R<2> are independently H, methyl, halo, carboxy, esterified carboxy, amidated carboxy, carboxymethyl, esterified carboxymethyl or amidated carboxymethyl; R<3> and R<4> (or each R<3> and R<4> group, when m or n is 2 or more) are independently selected from halo, amino, nitro, cyano, sulphamoyl, sulphonyl, trifluoromethyl, C1 to C3 alkyl, C1 to C3 alkoxy, hy...

Compounds of formula I (I) wherein G, J, L, M, m and D have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

PCT No. PCT/GB94/01803 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Aug. 17, 1994 PCT Pub. No. WO95/05169 PCT Pub. Date Feb. 23, 1995Certain flavonoids, notably derivatives of flavone, chrysin and apigenin, together with dimers thereof such as amentoflavone, have been found to possess anxiolytic properties (i.e., anxiety reducing properties) without exhibiting a sedative effe...

The present invention relates to methods of lessening the severity and frequency of adverse effects associated with administration of extracellular hemoglobin comprising administration of a smooth muscle relaxant. Preferred smooth muscle relaxants are terbutaline and nifedipine, which can be administered in a prophylactic treatment, responsive regimented treatment or responsive intermittent treatm...

This invention relates to carbocyclic and heterocyclic fused-ring quinolinecarboxylic acid compounds, to pharmaceutical compositions comprising such compounds, and to methods of using such compounds for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, chronic inflammatory diseases, including but not limited to psoriasis and rheumat...

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV viru...

Imidazolinobenzodiazepines are cholecystokinin B (CCK-B) antagonists useful as anxiolytic agents. The compounds have structures such as (I) and (II).

A solid oral sustained release oxybutynin formulation includes a sustained release matrix including a gelling agent, an inert pharmaceutical diluent, and a cationic cross-linking agent.

The subject invention involves topical depilatory compositions, at a pH of 7 or below, comprising sulfhydryl compounds. The subject invention further relates to methods for removing vellus hair from mammalian skin comprising topical application of a composition, at a pH of 7 or below, comprising a sulfhydryl compound or a cosmetically- and/or pharmaceutically- acceptable salt thereof.

Disclosed is a cross-linked ethylenic polymer foam structure of an ethylenic polymer material of a cross-linked, substantially linear ethylenic polymer. The substantially linear ethylenic polymer having in an uncross-linked state has: a) a melt flow ratio, I10/I2, >/=5.63; b) a molecular weight distribution, Mw/Mn, defined by the equation: Mw/Mn<(I10/I2)-4.63; and c) a critical shear rate at onset...

PCT No. PCT/EP94/01741 Sec. 371 Date Feb. 5, 1996 Sec. 102(e) Date Feb. 5, 1996 PCT Filed May 27, 1994 PCT Pub. No. WO92/28029 PCT Pub. Date Dec. 8, 1994A process is disclosed for producing thermoplastic starch based on renewable raw materials and, if required, for further processing it into a granulate. A low viscosity starch is modified under a low shearing stress during the extrusion process an...

Process for improving mechanical properties of an aged polyester composition consisting essentially of copolymer of hydroxybutyrate units and hydroxyvalerate units which comprises heating the polyester at a temperature whereby (i) the polyester is restored to its original non-aged properties, and (ii) subsequent ageing of the polyester is retarded as indicated by substantial improvement of at leas...

PCT No. PCT/GB94/01184 Sec. 371 Date Apr. 25, 1996 Sec. 102(e) Date Apr. 25, 1996 PCT Filed Jun. 1, 1994 PCT Pub. No. WO94/28061 PCT Pub. Date Dec. 8, 1994Polyester composition comprising a biodegradable polyester and a plasticising quantity of at least one plasticiser selected from the group: high-boiling esters of polybasic acids; phosphoric acid derivatives; phosphorous acid derivatives; phosph...

The application relates to a detergent composition or additive comprising a high level of bleach, a lipase and a double coated protease (e.g. Savinase 4.0 CT +). Also the use of said composition or additive wherein the lipolytic activity in the presence of protease remains unchanged is described.

Ashless dispersants are formed using polymers of propylene characterized in that they are liquid substantially linear polymers, they have stereo-irregularity in the polymer chain, at least 60 mol percent of the polymer has a terminal vinylidene group and, optionally, the polymer contains up to 25 mol percent of ethylene or a C4 to C10 monoolefin polymerized into the polymer chains.

PCT No. PCT/BE94/00041 Sec. 371 Date Feb. 26, 1996 Sec. 102(e) Date Feb. 26, 1996 PCT Filed Jun. 16, 1994Process for degumming a fatty substance such as a crude or delecithinated, animal or vegetable oil or fat, including bringing this fatty substance into contact with an aqueous solution of a complexing agent and of a detergent and/or emulsifier making it possible to hydrate the phospholipids pre...

PCT No. PCT/FR94/00804 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Jun. 30, 1994 PCT Pub. No. WO95/01403 PCT Pub. Date Jan. 12, 1995The invention relates to a mixture in powder form and comprising (i) at least one polyamide and (ii) at least one polymer (A) containing hydroxyl functional groups and compatible with the polyamide. The polymer (A) may be an ethylene/vinyl alcoh...

Polyisocyanate based organic aerogels having pore sizes less than 100 nm, densities in the range 10 to 800 kg/m<3> and surface areas in the range 10 to 1500 m<2>/g are provided.